WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Nov. 16, 2005--Dermisonics, Inc. (OTCBB: DMSI) (FWB: FQC), a developer of painless, injection-free, ultrasonic transdermal drug-delivery patches and technologies with broad pharmaceutical and consumer applications, today announced the launch of clinical trials to test for skin sensitivity to its U-Strip(TM) Insulin Patch on patients with Type-2 diabetes. The trials, an essential part of the clinical phase of Dermisonics’ transformative transdermal drug delivery method called the U-Strip(TM), is a precursor to the completion of Phase-1 Clinical Evaluations in the Company’s mission to commercialize the proprietary technology platform for the $5.4 billion insulin delivery marketplace. They mark an initial milestone achievement in the drug-delivery development, approval and commercialization process.
